He Jian, Meng Mei, Wang Hui
State Key Laboratory of Oncogenes and Related Genes, Center for Single-Cell Omics, School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
J Clin Transl Hepatol. 2022 Feb 28;10(1):90-103. doi: 10.14218/JCTH.2021.00047. Epub 2021 Sep 17.
LPAR6 is the most recently determined G protein-coupled receptor of lysophosphatidic acid, and hardly any study has demonstrated the performance of LPAR6 in cancers. We sought to clarify the relationship of LPAR6 to prognosis potential and tumor infiltration immune cells in different cancers.
The expression of LPAR6 and its clinical characteristics were evaluated on various databases. The association between LPAR6 and immune infiltrates of various types of cancer were investigated via TIMER.
We determined that higher LPAR6 expression level was associated with a better overall survival. Additionally, high LPAR6 expression level was significantly associated with better disease-specific survival (DSS) in bladder cancer, and better overall survival (OS)/ progression-free survival (PFS)/ distant metastasis-free survival (DMFS)/ relapse-free survival (RFS) in breast cancer and some other types of cancers. Moreover, LPAR6 significantly affects the prognosis of various cancers via The Cancer Genome Atlas (TCGA). Further research exposed that the mRNA level of LPAR6 was positively coordinated with infiltrating levels of devious immune cells in hepatocellular carcinoma.
Our results imply that LPAR6 is associated with prognosis potential and immune infiltration levels in liver cancer. Moreover, LPAR6 expression possibly contributes to the activation of CD8+ T, naive T, effector T cells and natural killer cells and inactivates T regulatory cells, decreases T cell exhaustion and regulate T helper cells in liver cancer. These discoveries imply that LPAR6 could be a novel biomarker of prognosis for indicating prognosis potential and immune-infiltrating level in hepatocellular carcinoma.
LPAR6是最近确定的溶血磷脂酸G蛋白偶联受体，几乎没有研究证明LPAR6在癌症中的表现。我们试图阐明LPAR6与不同癌症预后潜力和肿瘤浸润免疫细胞的关系。
在各种数据库中评估LPAR6的表达及其临床特征。通过TIMER研究LPAR6与各种癌症免疫浸润之间的关联。
我们确定较高的LPAR6表达水平与较好的总生存期相关。此外，高LPAR6表达水平与膀胱癌更好的疾病特异性生存期（DSS）以及乳腺癌和其他一些类型癌症更好的总生存期（OS）/无进展生存期（PFS）/无远处转移生存期（DMFS）/无复发生存期（RFS）显著相关。此外，LPAR6通过癌症基因组图谱（TCGA）显著影响各种癌症的预后。进一步研究发现，LPAR6的mRNA水平与肝细胞癌中迂回免疫细胞的浸润水平呈正相关。
我们的结果表明，LPAR6与肝癌的预后潜力和免疫浸润水平相关。此外，LPAR6的表达可能有助于激活CD8 + T细胞、幼稚T细胞、效应T细胞和自然杀伤细胞，并使调节性T细胞失活，减少T细胞耗竭并调节肝癌中的辅助性T细胞。这些发现表明，LPAR6可能是一种新的预后生物标志物，用于指示肝细胞癌的预后潜力和免疫浸润水平。
